The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Abstract
Four persons developed marked parkinsonism after using an illicit drug intravenously. Analysis of the substance injected by two of these patients revealed primarily 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) with trace amounts of 1-methyl-4-phenyl-4-propionoxy-piperidine (MPPP). On the basis of the striking parkinsonian features observed in our patients, and additional pathological data from one previously reported case, it is proposed that this chemical selectively damages cells in the substantia nigra.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most compelling evidence of mitochondrial dysfunction in PD comes from the accidental discovery of the synthetic meperidine analogue 1-methyl-4-phenyl-1,2,3,6-tetrahydrodropyridine (MPTP), which causes parkinsonism by selective inhibition of mitochondrial complex-I of the electron transport chain4, 5.”
From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [4]
Citations
Cites
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,377
GOLDSTEIN, J. E., & COGAN, D. G. (1965) · Archives of Ophthalmology · doi:10.1001/archopht.1965.00970030157003 · Cited by 129
PIPERIDINE DERIVATIVES. PART III. 4-ARYLPIPERIDINES1
Ziering, A., BERGER, L., HEINEMAN, S. D., et al. (1947) · The Journal of Organic Chemistry · doi:10.1021/jo01170a022 · Cited by 65
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–117 of 117
Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinson’s Disease
Leggio, L., Paternò, G., Vivarelli, S., Falzone, G. G., Giachino, C., Marchetti, B., & Iraci, N. (2021) · Aging and disease · doi:10.14336/ad.2021.0527 · Cited by 55
Wang, C., Sadovova, N., Ali, H. K., Duhart, H. M., Fu, X., Zou, X., Patterson, T. A., Binienda, Z. K., Virmani, A., Paule, M. G., et al. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.08.083 · Cited by 55
Ostendorf, F., Metzdorf, J., Gold, R., Haghikia, A., & Tönges, L. (2020) · Molecules · doi:10.3390/molecules25112502 · Cited by 46
Belin, A. C., Björk, B. F., Westerlund, M., Galter, D., Sydow, O., Lind, C., Pernold, K., Rosvall, L., Håkansson, A., Winblad, B., et al. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.05.010 · Cited by 48
Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease
Reich, N., & Hölscher, C. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.614828 · Cited by 48
“Given the pivotal role of mitochondrial dysfunction in PD, toxins that are selectively taken up by dopaminergic neurons and impair mitochondrial complex 1, such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), kill SN-located, dopaminergic neurons and induce Parkinsonism in humans and rodents (see Figure 2) (La…”
BackgroundMitochondrial medicine and the neurodegenerative mitochondriopathies
Swerdlow, R. H. (2009) · Pharmaceuticals · doi:10.3390/ph2030150 · Cited by 43
Sharifi-Rad, J., Bahukhandi, A., Dhyani, P., Sati, P., Capanoglu, E., Docea, A. O., Al-Harrasi, A., Dey, A., & Calina, D. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.664197 · Cited by 43
Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson’s disease
Andersen, J. K. (2003) · Neurotoxicity Research · doi:10.1007/bf03033150 · Cited by 40
Takazawa, C., Fujimoto, K., Homma, D., Sumi-Ichinose, C., Nomura, T., Ichinose, H., & Katoh, S. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.01.028 · Cited by 37
Tam, S. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8012 · Cited by 34
H. Swerdlow, R. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798072535 · Cited by 35
Wang, H., Dou, S., Zhu, J., Shao, Z., Wang, C., & Cheng, B. (2020) · Brain Research · doi:10.1016/j.brainres.2020.147023 · Cited by 33
Hineno, T., Mizobuchi, M., Hiratani, K., Inami, Y., & Kakimoto, Y. (1992) · Brain Research · doi:10.1016/0006-8993(92)90930-8 · Cited by 34
Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson’s disease
Patki, G. (2009) · Frontiers in Aging Neuroscience · doi:10.3389/neuro.24.003.2009 · Cited by 20
Pesticides and the Gut Microbiota: Implications for Parkinson’s Disease
Ghosh, N., Sinha, K., & Sil, P. C. (2024) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.4c00057 · Cited by 11
Mitochondrial Function and Neurodegenerative Diseases
Wilkins, H. M., Weidling, I., Koppel, S., Wang, X., von Schulze, A., & Swerdlow, R. H. (2018) · The Molecular and Cellular Basis of Neurodegenerative Diseases · doi:10.1016/b978-0-12-811304-2.00013-4 · Cited by 2
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
Self-citation
Metadata
- Authors
- Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I.
- ORCID
- Ballard, Philip
- Venue
- Science
- Published
- 1983-02-25
- Volume
- 219
- Issue
- 4587
- Pages
- 979-980
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1969800514
- Cited by
- 4,914
- References
- 3
- Citations by year
- 2026: 54 · 2025: 73 · 2024: 88 · 2023: 105 · 2022: 120 · 2021: 126 · 2020: 156 · 2019: 116 · 2018: 135 · 2017: 149 · 2016: 104 · 2015: 121 · 2014: 131 · 2013: 146 · 2012: 151
- FWCI
- 122.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- parkinsonism, MPTP, intravenous drug use, substantia nigra, neurotoxicity, Parkinson's disease
- MeSH terms
- Adult, Female, Humans, Male, Meperidine, Opioid-Related Disorders, Parkinson Disease, Secondary, Substantia Nigra
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
